Bajaj Healthcare Receives CDSCO Approval for Phase III Suvorexant Trials in India
Key Insights
Bajaj Healthcare Limited (search) has received positive recommendation from CDSCO (search)'s Subject Expert Committee to initiate Phase III clinical trials for Suvorexant tablets in multiple strengths for insomnia treatment.
The company becomes the first in India to secure regulatory clearance for Suvorexant, marking a significant milestone in addressing unmet medical needs for sleep disorders.
Phase III trials will evaluate efficacy, safety, and tolerability across diverse patient populations, representing the final stage before regulatory submission for marketing authorization.
Bajaj Healthcare Limited (search) has achieved a significant regulatory milestone by receiving positive recommendation from the Subject Expert Committee (SEC) for Neurology & Psychiatry of the Central Drugs Standard Control Organisation (CDSCO (search)) to initiate Phase III clinical trials for Suvorexant tablets in India. The approval covers tablet strengths of 5mg, 10mg, 15mg, and 20mg, making Bajaj Healthcare the first company in India to secure this regulatory clearance for the insomnia medication.
Mechanism and Clinical Application
Suvorexant is a prescription medication specifically designed to treat insomnia in adults by modulating the sleep-wake cycle through the central nervous system. The drug works by promoting improved sleep onset and maintenance, addressing key challenges faced by patients with sleep disorders.
Phase III Trial Design and Objectives
The upcoming Phase III clinical trials will evaluate the efficacy, safety, and tolerability of Suvorexant across a diverse patient population. This represents the final and most crucial step before regulatory submission, with the company planning to pursue marketing authorization in select markets upon successful completion of the trials.
Strategic Significance for CNS Portfolio
Anil Jain, Managing Director of Bajaj Healthcare Limited (search), emphasized the company's commitment to advancing the drug through final clinical development stages. "We are encouraged by the SEC's recommendation and remain committed to advancing Suvorexant through the final stages of clinical development," Jain stated. "With our robust R&D infrastructure and GMP-compliant manufacturing capabilities, we are confident in our ability to deliver high-quality, impactful CNS solutions to patients worldwide."
The development strengthens Bajaj Healthcare's neurology portfolio and aligns with the company's strategic vision of addressing unmet medical needs in chronic and lifestyle-related disorders.
Company Background and Manufacturing Capabilities
Established in 1993, Bajaj Healthcare Limited (search) specializes in manufacturing intermediates, APIs, formulations, and nutraceuticals. The company operates state-of-the-art manufacturing facilities designed to meet requirements for both advanced and emerging market opportunities, with a strong global presence across Europe, USA, Australia, Middle East, and South America.
Market Response
Following the regulatory announcement, Bajaj Healthcare's shares ended at ₹482.60 on the BSE, representing an increase of ₹2.95 or 0.62%, reflecting positive market sentiment toward this clinical development milestone.